Artemether-Lumefantrine and Primaquine for MixedPlasmodium falciparumandovaleMalaria

Preformulation Studies of Artemether, Quinine and Artemether-Lumefantrine Intended for Fixed-Dose Suppository Formulations

Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malaria.

BACKGROUND The World Health Organization recommends artemether-lumefantrine for treating uncomplicated malaria. We sought evidence of superiority of the six-dose regimen over existing treatment regimens as well as its effectiveness in clinical situations. OBJECTIVES To evaluate the six-dose regimen of artemether-lumefantrine for treating uncomplicated falciparum malaria. SEARCH STRATEGY We ...

Artemether-lumefantrine for uncomplicated malaria: a systematic review.

BACKGROUND The World Health Organization (WHO) is promoting artemether-lumefantrine for treating uncomplicated malaria. The objective of this review is to summarize available evidence of its effects compared with other antimalarial regimens. METHODS We sought randomized and quasi-randomized studies comparing artemether-lumefantrine with any other antimalarial drug regimen. Databases searched ...

Quality Assessment of Artemether-Lumefantrine Samples and Artemether Injections Sold in the Cape Coast Metropolis.

Most prescribers and patients in Ghana now opt for the relatively expensive artemether/lumefantrine rather than artesunate-amodiaquine due to undesirable side effects in the treatment of uncomplicated malaria. The study sought to determine the existence of substandard and/or counterfeit artemether-lumefantrine tablets and suspension as well as artemether injection on the market in Cape Coast. S...

Mass campaigns with antimalarial drugs: A modeling comparison of artemether-lumefantrine and 1 DHA-piperaquine with and without primaquine as tools for malaria control and elimination

Mass campaigns with antimalarial drugs: A modeling comparison of artemether-lumefantrine and 1 DHA-piperaquine with and without primaquine as tools for malaria control and elimination 2 3 Jaline Gerardin*, Philip Eckhoff, Edward A. Wenger 4 Institute for Disease Modeling, Intellectual Ventures, 1555 132 nd Ave NE, Bellevue WA 98005 USA 5 [email protected], [email protected], ewenger@intven...